Semin Liver Dis 2013; 33(S 01): S3-S10
DOI: 10.1055/s-0033-1333631
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Multidisciplinary Management of Hepatocellular Carcinoma: Where Are We Today?

Jorge A. Marrero
1   Medical Director of Liver Transplantation, UT Southwestern Medical Center, Dallas, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
01 March 2013 (online)

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide, and the incidence of HCC continues to rise. Improved understanding of risk factors for HCC has allowed the development of more effective prevention and surveillance strategies to reduce the global burden of this malignancy. Because of the complex nature of HCC, arising in a background of chronic liver dysfunction and often associated with viral infection, appropriate treatment requires a multidisciplinary approach designed to control the cancer and treat the underlying liver disease. Treatment approaches vary based on disease stage and severity, making accurate diagnosis and staging of disease critical. This has been aided by the development of new staging criteria, such as the Barcelona Clinic Liver Cancer Staging System. For earlier-stage disease, resection, radiofrequency ablation, transplantation, and transarterial chemoembolization (TACE) are preferred treatment modalities that provide optimal outcome. Until recently, few treatment options existed for patients with more advanced disease. Improved understanding of the underlying biology of the disease and the development of molecularly targeted therapies, including the multitargeted angiokinase inhibitor sorafenib, has improved outcomes in this patient population. Research into therapeutic targets and novel agents continues for more advanced disease.

 
  • References

  • 1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence, Mortality and Prevalence Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer: 2010. . Available at: http://globocan.iarc.fr/ . Accessed June 6, 2012
  • 2 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (2) 69-90
  • 3 Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27 (9) 1485-1491
  • 4 American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012. . Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf . Accessed on January 21, 2012
  • 5 London WT, McGlymm KA. Liver cancer. In: Schottenfeld D, Fraumeni Jr FJ, , eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 763-786
  • 6 Kiyosawa K, Umemura T, Ichijo T , et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127 (5) (Suppl. 01) S17-S26
  • 7 Donato F, Tagger A, Chiesa R , et al; for the BRESCIA HCC Study. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 1997; 26 (3) 579-584
  • 8 Hassan MM, Hwang L-Y, Hatten CJ , et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36 (5) 1206-1213
  • 9 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126 (2) 460-468
  • 10 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348 (17) 1625-1638
  • 11 Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42 (2) 218-224
  • 12 Chen D-S. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010; 25 (1) 19-25
  • 13 Liaw Y-F, Sung JJ, Chow WC , et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15) 1521-1531
  • 14 Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54 (4) 1433-1444
  • 15 Röcken C, Carl-McGrath S. Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 2001; 19 (4) 269-278
  • 16 Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31 (4) 339-346
  • 17 Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3) 1020-1022
  • 18 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130 (7) 417-422
  • 19 Singal A, Volk ML, Waljee A , et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30 (1) 37-47
  • 20 Thompson Coon J, Rogers G, Hewson P , et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11 (34) 1-206
  • 21 Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19 (11) 1159-1172
  • 22 Singal AG, Conjeevaram HS, Volk ML , et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21 (5) 793-799
  • 23 National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V 2.2012. Available at: www.nccn.org . Accessed July 3, 2012
  • 24 Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57 (11) 1592-1596
  • 25 Tremosini S, Forner A, Boix L , et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 2012; 61 (10) 1481-1487
  • 26 Okuda K, Ohtsuki T, Obata H , et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56 (4) 918-928
  • 27 The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28 (3) 751-755
  • 28 The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31 (4) 840-845
  • 29 Leung TW, Tang AM, Zee B , et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94 (6) 1760-1769
  • 30 Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38 (3) 207-215
  • 31 Vauthey JN, Lauwers GY, Esnaola NF , et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20 (6) 1527-1536
  • 32 Fleming ID. AJCC/TNM cancer staging, present and future. J Surg Oncol 2001; 77 (4) 233-236
  • 33 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (3) 329-338
  • 34 Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30 (1) 61-74
  • 35 Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, , ed. The Liver and Portal Hypertension. Philadelphia, PA: Saunders; 1964: 50-64
  • 36 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60 (8) 646-649
  • 37 Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009; 373 (9664) 614-616
  • 38 Marrero JA, Fontana RJ, Barrat A , et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41 (4) 707-716
  • 39 Llovet JM, Di Bisceglie AM, Bruix J , et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100 (10) 698-711
  • 40 Llovet JM, Fuster J, Bruix J ; for the Barcelona Clinic Liver Cancer Group. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30 (6) 1434-1440
  • 41 Imamura H, Matsuyama Y, Tanaka E , et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38 (2) 200-207
  • 42 Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991; 14 (5) 802-805
  • 43 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999; 229 (2) 216-222
  • 44 Adachi E, Maeda T, Matsumata T , et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108 (3) 768-775
  • 45 Okada S, Shimada K, Yamamoto J , et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106 (6) 1618-1624
  • 46 Morimoto O, Nagano H, Sakon M , et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 2003; 39 (2) 215-221
  • 47 Mazzaferro V, Romito R, Schiavo M , et al; HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44 (6) 1543-1554
  • 48 Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien P-A. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96 (9) 975-981
  • 49 Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000; 31 (4) 899-906
  • 50 Sala M, Fuster J, Llovet JM , et al; Barcelona Clinic Liver Cancer (BCLC) Group. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004; 10 (10) 1294-1300
  • 51 Mazzaferro V, Regalia E, Doci R , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
  • 52 Yao FY, Ferrell L, Bass NM , et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (6) 1394-1403
  • 53 Ioannou GN, Perkins JD, Carithers Jr RL. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134 (5) 1342-1351
  • 54 Llovet JM, Mas X, Aponte JJ , et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50 (1) 123-128
  • 55 Stone MJ, Klintmalm GB, Polter D , et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993; 104 (1) 196-202
  • 56 Pokorny H, Gnant M, Rasoul-Rockenschaub S , et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?. Am J Transplant 2005; 5 (4 Pt 1) 788-794
  • 57 Majno PE, Adam R, Bismuth H , et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226 (6) 688-701 , discussion 701–703
  • 58 Millonig G, Graziadei IW, Freund MC , et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13 (2) 272-279
  • 59 Clavien PA, Lesurtel M, Bossuyt PM, Gores G-J, Langer B, Perrier A. on behalf of the OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (1) e11-e22
  • 60 United States Department of Health and Human Services. Organ Procurement and Transplant Network. Available at: www.optn.transplant.hrsa.gov . Accessed June 28, 2012
  • 61 Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49 (2) 453-459
  • 62 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262 (1) 43-58
  • 63 N'Kontchou G, Mahamoudi A, Aout M , et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50 (5) 1475-1483
  • 64 Chen M-S, Li J-Q, Zheng Y , et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 (3) 321-328
  • 65 Livraghi T, Meloni F, Di Stasi M , et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?. Hepatology 2008; 47 (1) 82-89
  • 66 Lu DS, Yu NC, Raman SS , et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234 (3) 954-960
  • 67 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (2) 429-442
  • 68 Llovet JM, Real MI, Montaña X , et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319) 1734-1739
  • 69 Lo CM, Ngan H, Tso WK , et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (5) 1164-1171
  • 70 Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther 2008; 8 (10) 1643-1650
  • 71 Grosso M, Vignali C, Quaretti P , et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008; 31 (6) 1141-1149
  • 72 Song MJ, Park CH, Kim JD , et al. Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 2011; 23 (6) 521-527
  • 73 Malagari K, Chatzimichael K, Alexopoulou E , et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008; 31 (2) 269-280
  • 74 Malagari K, Pomoni M, Kelekis A , et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33 (3) 541-551
  • 75 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
  • 76 Salem R, Lewandowski RJ, Mulcahy MF , et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (1) 52-64
  • 77 Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977; 61 (7) 1385-1387
  • 78 Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985; 56 (12) 2751-2755
  • 79 Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984; 68 (3) 487-491
  • 80 Qin S, Bai Y, Ye S , et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol 2010; 28 (15S) : Abstract 4008
  • 81 Llovet JM, Ricci S, Mazzaferro V , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4) 378-390
  • 82 Cheng AL, Kang YK, Chen Z , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1) 25-34
  • 83 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1) 52-60
  • 84 Edeline J, Boucher E, Rolland Y , et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118 (1) 147-156
  • 85 Marrero J, Lencioni R, Kudo M , et al. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction. J Clin Oncol 2011; 29 (Suppl): Abstract 4001